Podcasts about fractyl

In this epsisode Prof. Francisco Giorgino & Dr. Vanita Aroda explore how vital it is that we aim to control more than blood glucose levels when treating type 2 diabetes patients and whether we should strive for a balance by achieving weight, cardiovascular and renal targets as well. For more free education, go to diabetes.knowledgeintopractice.com⁠, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice⁠) or connect on LinkedIn⁠. Disclosures Prof. Francisco Giorgino: Grants or contracts: Eli Lilly, Roche Diabetes Care Consulting: Eli Lilly, Novo Nordisk Honoraria for lectures, presentations and education events: Astra-Zeneca, Boehringer-Ingelheim Advisory boards: Eli Lilly, Lifescan, Merck Sharp & Dohme, Medimmune Leadership or fiduciary role in other board: EASD/EFSD, (SIE), Fo.Ri SIE Receipt of equipment, materials, drugs, medical writing, gifts or other services: AstraZeneca, Eli Lilly, Novo Nordisk Unlabelled use of drugs or devices: Roche Diabetes Care, Sanofi Dr. Vanita Aroda: Consulting: Applied Therapeutics, Fractyl, Pfizer, Novo Nordisk, Sanofi Research Support: Applied Therapeutics, Eli Lilly, Fractyl, Novo Nordisk, Sanofi Target Audience: Specialty: Primary care physicians (PCPs), endocrinologists, cardiologists, diabetologists Geographic: Global (ex US and UK audiences) Funding Information: This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S, has had no influence on the content of this education.

In der Mittagsfolge begrüßen wir heute Julian Lindinger, Co-Founder von PowerUs, und sprechen mit ihm über die erfolgreiche Finanzierungsrunde in einer Gesamthöhe von 10 Millionen US-Dollar. PowerUs hat eine Karriereplattform entwickelt, um technische Fachkräfte aus Ausbildungsberufen dabei zu helfen, ihr Karrierepotential zu entfalten. Dafür bringt die Plattform die qualifizierten Arbeiterinnen und Arbeiter mit Unternehmen zusammen, indem sie eine Kombination aus einem sozialen Netzwerk für Geschäftskontakte und einem Jobportal darstellt. Zudem wurde ein erster kostenloser Online-Kurs gestartet, mit dem Expertinnen und Experten eines anderen Fachgebiets der Einstieg in die Solarbranche ermöglicht werden kann. Weitere Online-Kurse sind bereits in Planung. PowerUs wurde im Jahr 2019 von Julian Lindinger und Konrad Geiger in Berlin gegründet. Das Startup beschäftigt mittlerweile 40 Mitarbeitende und möchte weiterhin personell wachsen. In einer Series-A-Finanzierungsrunde hat das Berliner Startup nun 10 Millionen US-Dollar eingesammelt. Der Risikokapitalgeber General Catalyst, der u.a. Airbnb, Canva, GitLab, Hive, Big Fish (Exit), Hubspot (Exit), Snap (Exit), Almanac, Anduril, Blade, Casana, Cityblock, Cozy, Empathy, Fundbox, Fractyl, Hometap, PathAI, Rapyd, Snackpass, Deliveroo und Stripe in seinem Portfolio hat, führte die Finanzierungsrunde an. Der Wagniskapitalgeber HV Capital, der u.a. in Delivery Hero, Hello Fresh, Zalando, Penta und Flixbus investiert hat, sowie das US-amerikanische Gründerzentrum Y Combinator haben sich ebenfalls als Bestandsinvestoren an der Serie A beteiligt. Des Weiteren haben sich auch Business Angels, wie u.a. Carsten Thoma, Mathis Büchi Ginzbourg, Philipp A. Pausder, Tomer London, Ben Shanken und Christian Hülsewig den VCs angeschlossen. Unter den investierenden Angels befindet sich auch Mario Götze, der u.a. bei Finanzierungen der Startups Pile, Knowunity, Virtex Stadium, Junto, Freeverse.io, Fancurve, Codesphere und Meine Erde beteiligt war. Mit dem frischen Kapital möchte das Berliner Startup hauptsächlich neue Talente einstellen und sein starkes Wachstum weiter voranbringen.

It's in the news! Got a few minutes? Get caught up! Top stories this week: Dexcom is reportedly in talks to buy Omnipod, Abbott & Dexcom sue and countersue each other over patents, new study showing people with type 1 diabetes are living longer, a JDRF advocate climbs Mt Everest, and more! Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story this week is still developing.. but Bloomberg reports that Dexcom is in talks to acquire Insulet, the makers of Omnipod. Neither company has commented publicly on the report. Bloombeg says, “Talks between the companies are ongoing and an agreement could be reached in the coming weeks, said the people, who asked not to be identified because the information is private. Discussions could still be delayed or fall apart, the people said.” Insulet's stock has gone up and Dexcom's has gone down. These companies already have an agreement in which the Omnipod and Dexcom CGMs communicate.. Dexcom also has an agreement with Tandem and some other companies – those aren't expected to change in the short term, but there are a lot more questions than answers about this report. I'm scheduled to talk to Dexcom's CEO in early June and we'll continue to follow this story. https://www.bloomberg.com/news/articles/2022-05-23/dexcom-is-said-in-talks-to-acquire-device-firm-insulet XX Meanwhile, Dexcom and Abbott are currently going head-to-head over twelve separate patents covering their respective CGMs. Both companies are launching newer products soon, with the Dexcom G7 and Freestyle Libre 3 already available in Germany. Dexcom first sued in 2021.. Abbot then countersued. A UK High Court will hold three separate technical trials, planned for December 2022, April 2023 and July 2023. https://www.juve-patent.com/news-and-stories/cases/dexcom-and-abbotts-fight-over-glucose-monitoring-patents-intensifies-in-europe/ XX People with type 1 diabetes are living longer according to a new study based on data from Australia, Denmark, Latvia, Scotland, Spain, and the United States. The years analyzed varied by country, but overall, they cover 2000 to 2016 and include 1.5 million person-years. The data show that country-by-country annual changes in age- and sex-standardized all-cause mortality among people with T1D dropped by between 2% and nearly 6% over the study period. The risk of dying was still higher than in people without type 1, mostly because of diabetes complications. https://www.ajmc.com/view/all-cause-mortality-falling-among-people-with-type-1-diabetes XX A new study finds that herpes virus may contribute increased risk of type 2 diabetes. Herpes viruses are one of the most common viruses in humans, with 8 types currently known. Any of these can cause lifelong latent infections after an initial, usually mild or asymptomatic primary infection. Until recently, viruses had only been proposed as a potential trigger for the development of type 1 diabetes. This study was based on health data from nearly 2000 people, men and women, in Germany. The researchers found that herpes viruses consistently and complementarily contributed to the development of prediabetes and diabetes, even after accounting for sex, age, BMI, education, smoking, physical activity, parental diabetes, hypertension, lipid levels, insulin resistance, and fasting glucose. https://www.pharmacytimes.com/view/study-herpesvirus-infection-may-increase-risk-of-diabetes XX This one sounds kind of odd, but a one-time diabetes treatment may lower average blood sugar and improve long-term insulin resistance and pancreatic function. The company is Fractyl, the treamtment is an outpatient proceure that applies heat to the intestinal walls to – quote – strip out and reset the mucosal lining, which can thicken over years from dietary fats, sugars and other foods. Fractyl believes this thickening contributes to the insulin resistance seen in Type 2 diabetes. The device has breakthrough FDA designation, but no approval yet. It is approved in Europe. https://www.fiercebiotech.com/medtech/fractyl-shows-its-intestine-resurfacing-device-type-2-diabetes-improves-insulin-resistance XX Right back to the news in a moment but first we've got a new sponsor. As I mentioned, The T1D Exchange Registry is an online research study, designed to harness the power of individuals with type 1 diabetes. It's a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy Sign up at T1DExchange.org slash Stacey (that's S-T-A-C-E-Y). XX XX Cameron Kenny just climbed Mt Everest and unfurled the JDRF flag at the summit. Kenny doesn't live with diabetes, but his brother does. Kenny is an accomplished climber and raised money for JDRF during his prep and climb of Everest. I can't seem to find his brother's name anywhere, even in the JDRF posts, so if you know this family, please let me know. XX On this week's long format episode, you'll hear about Mike Joyce is set to complete an incredible long-distance hiking trail. It's actually three trails – the longest in the US – he'll talk about how he does this with type 1. Next week, type one way ticket travel – a new way to get teenagers with T1D to experience international adventure travel. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

People with type 2 diabetes are at high risk of developing NASH, increasing their risk of poor outcomes. However, the only way to confirm a diagnosis of NASH is through liver biopsy, so how can we help identify people with NASH? This episode examines the currently available approaches to identifying NASH with Professor Arun Sanyal. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References: European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7. PMID: 27062661. Chalasani N, et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357 Disclosures: Professor Arun Sanyal discloses: Consulting advisor: Conatus, GenFit, Gilead, malinckrodt, Pfizer, Salix, Boehringer Ingelhiem, Immuron, Intercept, Novartis, Bristol Myers, Merck, Hemoshear, Lilly, Novo Nordisk, Terns, Galectin, Sequana, Fractyl, Amra, Albireo, Sanofi, Jannsen, Takeda, Northsea, Owl, Poxel, 89 Bio, Siemens, Ngm Bio, Perspectum, Astra Zeneca, Biocellvia, Regeneron, Genentech, Roche, Madrigal, Inventiva, Albireo, Covance, Prosciento, Histoindex, Path Ai Research grants: Conatus, Gilead, Echosense-sandhill, Malinckrodt, Immuron, Boehringer Ingelhiem, Novartis, Bristol Myers, Merck, Lilly, Novo Nordisk, Fractyl, Owl, Second Genome, Siemens, Madrigal, Inventiva, Covance Royalties: Elsevier, Uptodate Stock: Sanyal Bio, Exhalenz, Akarna, Genfit, Hemoshear, Durect, Indalo, Tiziana, Rivus This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

This episode's Community Champion Sponsor is Catalyst. To virtually tour Catalyst and claim your space on campus, or host an upcoming event: https://www.catalysthealthtech.com/ (CLICK HERE) --- As we celebrate the 100th anniversary of the discovery of insulin, it may seem that type 2 diabetes treatment has come a long way. However, therapeutics and treatment have evolved very little since 1921. Our next guest is a scientist turned entrepreneur who is determined to create innovative breakthroughs that address the root cause of type 2 diabetes. By leveraging his groundbreaking insights of the intestine's role in metabolic disease, his company is developing entirely new treatment approaches to type 2 diabetes and other metabolic diseases. Dr. Harith Rajagopalan, CEO of Fractyl Health, joins us to discuss his vision of a healthier society free from the burdens of metabolic diseases and how you can get involved.  Join us as Dr. Rajagopalan shares his journey towards changing the trajectory of metabolic disease risk that will move the health of our communities forward. Let's go! Episode Highlights: Dr. Rajagopalan's career change from physician to entrepreneur  Fractal Health's origin story and the company's passion of tackling the root cause of diabetes Why gut health is so important for overall health Fractal Health's long-term goal of reducing the risk of various metabolic diseases  About our Guest:  Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women's Hospital and completed a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School. Links Supporting This Episode: Fractyl Health website: https://www.fractyl.com/ (CLICK HERE) Dr. Harith Rajagopalan LinkedIn page: https://www.linkedin.com/in/harith-rajagopalan-fractyl/ (CLICK HERE) Fractyl Health Twitter page: https://twitter.com/FractylHealth (CLICK HERE) Clubhouse handle: @mikebiselli Mike Biselli LinkedIn page: https://www.linkedin.com/in/mikebiselli (CLICK HERE) Mike Biselli Twitter page: https://twitter.com/mikebiselli (CLICK HERE) Visit our website: https://www.passionatepioneers.com/ (CLICK HERE) Subscribe to newsletter: https://forms.gle/PLdcj7ujAGEtunsj6 (CLICK HERE) Guest nomination form: https://docs.google.com/forms/d/e/1FAIpQLScqk_H_a79gCRsBLynkGp7JbdtFRWynTvPVV9ntOdEpExjQIQ/viewform (CLICK HERE) Support this podcast

Harith Rajagopalan, M.D., Ph.D., Co-Founder & CEO, Fractyl Dr. Harith Rajagopalan is co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners. Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in chemistry from Stanford University and went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine. At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. After medical school, Harith trained in internal medicine and clinical cardiology at Brigham and Women's Hospital and completed a research fellowship at Harvard Medical School.   

In this week’s episode of the DeviceTalks Weekly podcast, co-hosts Tom Salemi, editorial director of DeviceTalks, and Chris Newmarker, executive editor of life sciences, review this week's Top 5 medtech stories, aka “Newmarker’s Newsmakers,” with news coming from CureVac, Avail Medsystems, ClearMask, Thermo Fisher and Bayer. We also hear from two executives from Fractyl Laboratories — CEO Dr. Harith Rajagopalan and CFO Lisa Davidson — about its recent $55 million Series E round of financing and the strides they're making in developing a device to treat diabetes. In a second interview, Cala Health CEO Renee Ryan gives us an update on the Cala Trio’s clinical success and how the start-up is working through COVID-19. Finally, Chris and Tom hint at an upcoming event for the DTW community.

Crystal McKellar is the Founder and Managing Partner of Anathem Ventures, an early-stage venture capital firm investing in companies that have developed breakthrough technology that they are pragmatically leveraging to win and own uncrowded, high-margin markets. Crystal currently serves on the board of Cooler Heads, and previously served as a board member at Siren, Neurable, and DoubleDutch (acquired by Cvent) and as a board observer at Fractyl.   Crystal is a Kauffman Fellows Mentor, and has served as a mentor to the TechStars MetLife Digital Accelerator and the Ad Astra tech incubator program. Crystal is a proud member of All Raise and is a frequent speaker on entrepreneurship and innovation at technology conferences and finance events. In this episode, you'll learn: When raising a fund, what recommendations are there for first-time fundraisers? What are the relationship dynamics between a Venture Capitalist and the Limited Partners (LPs)? The life of a VC, how is it really? What are some of the positives and negatives of the role? What are the advantages of keeping the fund size small?   We would like to thank Maya Tussing for making the introduction which allowed for today's episode. Thank you for the support! HELP US OUT!   Please take a few seconds and leave us a positive review as it helps the show grow and motivates us to create content. Thank you for helping and giving back to the show!   CONNECT WITH CRYSTAL LinkedIn| Website | Email  CONNECT WITH SHAWN: https://linktr.ee/ShawnflynnSV   Shawn Flynn's Twitter Account Shawn Flynn's LinkedIn Account Silicon Valley LinkedIn Group Account Shawn Flynn's Facebook Account Change to Shawn@thesiliconvalleypodcast.com      

Crystal McKellar is the Founder and Managing Partner of Anathem Ventures, an early-stage venture capital firm investing in companies that have developed breakthrough technology that they are pragmatically leveraging to win and own uncrowded, high-margin markets. Crystal currently serves on the board of Cooler Heads, and previously served as a board member at Siren, Neurable, and DoubleDutch (acquired by Cvent) and as a board observer at Fractyl. Crystal is a Kauffman Fellows Mentor, and has served as a mentor to the TechStars MetLife Digital Accelerator and the Ad Astra tech incubator program. Crystal is a proud member of All Raise and is a frequent speaker on entrepreneurship and innovation at technology conferences and finance events.In this episode, you’ll learn:When raising a fund, what recommendations are there for first-time fundraisers?What are the relationship dynamics between a Venture Capitalist and the Limited Partners (LPs)?The life of a VC, how is it really? What are some of the positives and negatives of the role?What are the advantages of keeping the fund size small?We would like to thank Maya Tussing for making the introduction which allowed for today’s episode. Thank you for the support!HELP US OUT!Help us reach new listeners by leaving us a rating and review! It takes less than 30 seconds and really helps our show grow, which allows us to bring on even better guests for you all! Thank you – we really appreciate it!Tweet your comments about this episode directly to Shawn Flynn and the rest of The Investor’s Podcast Community using #TIPSiliconValley.BOOKS AND RESOURCESDownload your free audiobook at Audible.Capital One. This is Banking Reimagined.Experience a real estate investing platform that is powered by an investor-first model with Fundrise.Make your money work harder with Wealthsimple.Affordable, private online counseling. Anytime, anywhere with Betterhelp. CONNECT WITH CRYSTALLinkedIn| Website | Email GET IN TOUCH WITH SHAWNShawn Flynn’s Twitter AccountShawn Flynn’s LinkedIn AccountSilicon Valley LinkedIn Group AccountShawn Flynn’s Facebook AccountEmail: Shawn@TheInvestorsPodcast.com

Using fractal-inspired therapeutics to help large populations of patients with metabolic disease https://outcomesrocket.health/fractyl/2019/12/

Harith Rajagopalan is a medical doctor, entrepreneur and co-founder of Fractyl, a biotechnology company based in Lexington, Massachusetts. Fractyl's stated mission is to solve the global epidemic of type 2 diabetes, a disease that stands in the way of a long and healthy life for so many people. Dr. Rajagopalan’s work focuses on a better understanding of the root cause of the disease and how diet-related damage to the inner surface of the small intestine leads to insulin resistance. The company has developed a clinical procedure to rejuvenate the duodenal surface, which helps patients reverse or even halt the progression of their diabetes. In this in-depth interview, recorded at TEDMED, Dr. Rajagopalan explains how the minimally invasive treatment works and how it could give hope to millions of patients who view diabetes as a progressive condition. He shares his evolving understanding of dietary practices, such as fat consumption and fasting - and explains why birthday cake should play a role in our lives.

What Went into Fractyl’s $44 million Round? CEO and co-founder Harith Rajagopalan, MD, PhD, discusses his approach to raising new capital and to building the right board.

Nim Shah left Domain Associates to take on the chief business officer role at hot Start-Up Fractyl Laboratories. Hear why he made the change, what he feels went wrong for Medtech, and what’s next for Fractyl.